Skip to main content
Clinical Trials/NCT00698347
NCT00698347
Terminated
N/A

A Prospective, Non-controlled, Clinical Investigation of the M2a-Magnum™ Hip System

Biomet Orthopedics, LLC0 sites249 target enrollmentNovember 2004

Overview

Phase
N/A
Intervention
Not specified
Conditions
Osteoarthritis, Hip
Sponsor
Biomet Orthopedics, LLC
Enrollment
249
Primary Endpoint
Harris Hip Score
Status
Terminated
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this prospective clinical data collection is to document the performance and clinical outcomes of the M2a-Magnum™ Hip System

Detailed Description

This is a 10 year prospective data collection documenting the function and survivorship of the M2a-Magnum™ Hip System. Patients are required to come in for preoperative, operative, one year follow-up, three year follow-up, five year follow-up, and ten year follow-up exams. This product was FDA cleared in 2004.

Registry
clinicaltrials.gov
Start Date
November 2004
End Date
January 2015
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Non-inflammatory degenerative joint disease including: Avascular Necrosis, Diastrophic Variant, Fracture of the Pelvis, Fused Hip, Leg Perthes, Osteoarthritis, Slipped Capital Epiphysis, Subcapital Fractures, Traumatic Arthritis
  • Rheumatoid Arthritis
  • Correction of Functional Deformity
  • Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
  • Revision of previously failed total hip arthroplasty

Exclusion Criteria

  • Absolute contraindications include:
  • Infection, Sepsis, and Osteomyelitis
  • Relative contraindications include:
  • Uncooperative patient or patient with neurologic disorders that are incapable of following directions
  • Osteoporosis
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may spread to the implant site
  • Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram
  • Vascular insufficiency, muscular atrophy, or neuromuscular disease

Outcomes

Primary Outcomes

Harris Hip Score

Time Frame: 10 years

Secondary Outcomes

  • Incidence of revisions, removals, and/or complications(Any time)
  • X-Rays(10 years)

Similar Trials